Pharma

Combination therapy produced broader psoriasis-related and metabolic biomarker changes vs Taltz alone as early as Week 12, with greater reductions in inflammatory and neutrophil markers.

Phase 3 data show sustained PASI90/PASI100 and IGA 0/1 responses to Week 112, durable itch improvement, and no new safety signals.

First patient dosed in a randomized Phase 2a trial of AIC468, an antisense oligonucleotide targeting BK virus in adult kidney transplant recipients.

FDA backs first adjuvant immunotherapy regimen for stage III dMMR colon cancer after ATOMIC showed a 50% reduction in recurrence or death with Tecentriq added to chemotherapy.

Adds local production of pMDI valves, breath‑actuated inhalation devices and multi dose nasal spray systems; site grows to 11,300 m² to improve regional supply resilience.

FDA acceptance of finerenone sNDA for adults with CKD without diabetes follows Phase III FIND‑CKD showing slower eGFR decline and reduced cardio‑kidney events versus placebo.

Independent Data Monitoring Committee advised stopping the trial for futility after an interim analysis; safety remained consistent and no new signals were seen.

FB102, a CD122 inhibitor, met the primary histology endpoint (Vh:Cd change; p=0.0176) versus placebo and showed aligned symptom and inflammatory benefits with no new safety signals.

China’s regulator approved a plant-based, water‑soluble CMC excipient for pharmaceutical manufacturing, enabling supply into China’s large drug production market.

Long-acting cabotegravir + rilpivirine achieved superior viral suppression versus standard oral ART at six months when initiated in people with detectable HIV.